The ATP6V0A2 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma epithelial line, engineered for disruption of ATP6V0A2. This loss-of-function model targets the a2 subunit of the vacuolar-type H?-ATPase V0 domain, enabling studies of proton translocation and organellar acidification in cancer contexts. The heterogeneous polyclonal pool ensures diverse mutational events without clonal bias. Researchers can employ this resource to dissect V-ATPase function in autophagy, endolysosomal biology, and cancer signaling.
The A-549 parental cell line is a human lung adenocarcinoma epithelial model widely used in cancer research for studying oncogenic signaling, tumor progression, and drug resistance. Originally derived from a patient, these adherent cells exhibit robust growth and genetic features representative of non-small cell lung cancer, making them ideal for functional genomics and high-throughput screening. Introduction of a CRISPR/Cas9-mediated ATP6V0A2 disruption in this background yields a polyclonal knockout population suitable for exploring V-ATPase-dependent lysosomal dynamics and metabolic reprogramming in lung adenocarcinoma, processes increasingly linked to malignancy.
ATP6V0A2 encodes the a2 subunit of the vacuolar-type H?-ATPase (V-ATPase) V0 domain, mediating proton translocation and organellar acidification essential for lysosomal/endosomal function. This subunit forms key interactions with V-ATPase core components, including ATP6V0C and ATP6V1A, and with accessory proteins such as ATP6AP1 and the Wnt co-receptor LRP6. Mechanistically, ATP6V0A2 acts upstream of mTORC1 by maintaining the acidic environment required for Rag GTPase-mediated recruitment and activation of mTORC1 on lysosomal surfaces. Consequently, its knockout impairs mTORC1-dependent phosphorylation of S6K1, disrupts autophagic flux through reduced LC3-II turnover and Cathepsin D maturation, and leads to TFEB nuclear translocation due to deficient mTORC1-mediated cytoplasmic sequestration. These interconnected nodes position ATP6V0A2 at the intersection of autophagy, mTOR signaling, and Wnt pathway regulation.
Disruption of ATP6V0A2 in A-549 cells impairs lysosomal acidification and autophagic degradation, leading to compromised mTORC1 signaling and altered cellular metabolism. This knockout model is valuable for investigating how V-ATPase activity influences lung adenocarcinoma cell survival, proliferation, and therapeutic resistance, particularly given the reliance of cancer cells on autophagy for stress adaptation. Additionally, it provides a cellular platform for modeling the pathogenesis of autosomal recessive cutis laxa type IIA and wrinkly skin syndrome at the molecular level, and for testing pharmacological agents that target V-ATPase-dependent pathways.
Typical applications include Western blot and RT-qPCR to confirm ATP6V0A2 knockout, immunofluorescence analysis of LAMP1 for lysosomal morphology, and autophagic flux assays measuring LC3-II turnover. Lysosomal pH probes and Seahorse metabolic analyzers provide functional readouts of acidification and metabolic changes. Cellular phenotypes such as viability, migration, and drug sensitivity can be quantitatively assessed, and the polyclonal pool is amenable to drug screening for V-ATPase inhibitors or autophagy modulators. For additional information or to request custom services, please contact Ascent Research.
